cytarabine has been researched along with Lassitude in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benjamin, K; Bui, CN; Devine, J; DiNardo, CD; Fiedler, W; Fracchiolla, N; Ivanov, V; Jonas, BA; Kamalakar, R; Kim, I; Mendes, W; Montesinos, P; Novak, J; Ofran, Y; Panayiotidis, P; Pejsa, V; Potluri, J; Pratz, KW; Recher, C; Schuh, AC; Stevens, D; Turgut, M; Wei, AH; Wei, X; Yamamoto, K; Yeh, SP | 1 |
| Bakare, BY; Bello, FO; Ojo, OT; Olatunji, AO; Olatunji, PO | 1 |
| Bertolini, F; Cassisa, A; Gasparin, P; Miggiano, MC | 1 |
| Arnold, AJ; Gilmour, GS; Koch, MW | 1 |
| Chen, YB; Dec, GW; Fathi, AT; Hasserjian, RP; Holmvang, G; Richter, JM; Schwartzenberg, SS | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Canning, C; DeAngelo, DJ; Galinsky, I; Janosova, A; Ritz, J; Soiffer, RJ; Stone, RM | 1 |
| Allen-Bard, S; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Segovia, J | 1 |
| D'Amore, ES; Finotto, S; Menin, A; Paolini, R; Pizzolo, G; Rodeghiero, F; Semenzato, G; Visco, C; Zaja, F; Zambello, R; Zanotti, R | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Atkins, JN; Capizzi, RL; Cooper, MR; Craig, J; Ferree, D; Homesley, HD; Jobson, V; McMahan, RA; Muss, HB; Powell, BL | 1 |
6 trial(s) available for cytarabine and Lassitude
| Article | Year |
|---|---|
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Fatigue; Feasibility Studies; Female; Fever; Follow-Up Studies; Humans; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Analysis; T-Lymphocytes; Thrombocytopenia; Time Factors; Treatment Outcome | 2008 |
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Oxides; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting | 2013 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cytarabine; Dexamethasone; Disease-Free Survival; Fatigue; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Multiple Myeloma; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine | 2007 |
6 other study(ies) available for cytarabine and Lassitude
| Article | Year |
|---|---|
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Fatigue; Humans; Leukemia, Myeloid, Acute; Quality of Life; Sulfonamides | 2022 |
A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager.
Topics: Anemia; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Blood Transfusion; Cytarabine; Daunorubicin; Fatigue; Female; Humans; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Lost to Follow-Up; Muscle Weakness; Thrombocytopenia; Young Adult | 2018 |
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; Etoposide; Fatal Outcome; Fatigue; Female; Fever; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Leukocytosis; Metrorrhagia; Middle Aged; Myoma; Neoplasms, Multiple Primary; Palliative Care; Skin; Uterine Neoplasms | 2017 |
Clinical Reasoning: A pregnant woman with chin numbness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chin; Consolidation Chemotherapy; Cytarabine; Emergency Service, Hospital; Fatigue; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypesthesia; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Paresthesia; Pregnancy; Pregnancy Complications, Neoplastic; Spinal Puncture; Sweating; Upper Extremity | 2019 |
Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy; Bone Marrow; Colitis, Ulcerative; Cytarabine; Diagnosis, Differential; Diarrhea; Eosinophilia; Fatigue; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Male; Rectum; Splenomegaly; Stomach; Ultrasonography | 2014 |
Phase I trials of high-dose cytosine arabinoside (HDara-C) and HDara-C plus cisplatin in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Fatigue; Humans; Kidney Diseases; Leukopenia; Middle Aged; Neoplasms; Thrombocytopenia | 1985 |